BeStock  
Stocks › Biotechnology › MLYS

Mineralys Therapeutics MLYS

US equityMarket cap rank #3034Biotechnology
$13.66 −$0.50 (-3.53%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $13.70 +0.29%
Open$13.81
Prev close$14.16
Day range$13.57 – $14.79
Volume1.35M
Market cap$1.21B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-3.6x
CheapRich

Near the top of its 5-year range · 94th percentile, 5-year average -8.9x

Price / book2.7x
CheapRich

Around its usual level · 54th percentile, 5-year average 2.1x

#3587 of 5330 stocks by PB (1 = cheapest)

P/E over five years

-24x-15x-7x2xFeb '23Dec '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$27.10
Price vs. fair value-49.6%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 2.69 – 2.11 54% (pricier than usual) #3587 of 5330 (1 = cheapest)
PE -3.57 -5.53 -8.91 94% (pricier than usual) –
PS – 40.07 0.00 – –

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on MLYS.

Sign in to join the discussion.

Scroll to Top